Literature DB >> 12518364

Patterns of disease recurrence influenced by hematogenous tumor cell dissemination in patients with cervical carcinoma of the uterus.

Wolfgang Janni1, Florian Hepp, Barbara Strobl, Brigitte Rack, Dorothea Rjosk, Christina Kentenich, Christian Schindlbeck, Peer Hantschmann, Klaus Pantel, Harald Sommer, Stephan Braun.   

Abstract

BACKGROUND: The presence of isolated tumor cells (ITC) in the bone marrow at the time of primary diagnosis indicates an increased risk for subsequent development of distant metastases in various solid tumors. This study evaluates the prevalence and prognostic significance of ITC in patients with primary carcinoma of the cervix uteri.
METHOD: We immunocytochemically analyzed bone marrow aspirates of 130 patients with newly diagnosed carcinoma of the cervix uteri for the presence of cytokeratin(CK)-positive cells from May 1994 to January 2001. We used a quantitative immunoassay with the monoclonal anti-CK antibody A45-B/B3 and evaluated 2 x 10(6) bone marrow cells per patient. Patients were followed prospectively for a median of 43 (range, 1-85) months.
RESULTS: Isolated tumor cells were found in the bone marrow of 38 patients (29%). The presence of ITC did not correlate with the International Federation of Gynecology and Obstetrics (FIGO) tumor stage (P = 0.61), pelvic and paraaortal lymph node involvement (P = 0.41), histopathologic grading (P = 0.67), the histologic type of the carcinoma (P = 0.93), invasion of lymph nodes (P = 0.93) and blood vessels (P = 0.92), or with menopausal status (P = 0.17). The bone marrow status at the time of primary diagnosis did not correlate with the overall survival as estimated by Kaplan-Meier analysis (P = 0.30). However, distant metastases occurred in 5% of the patients (n = 5) with negative bone marrow status and in 15% of the patients (n = 6) with positive bone marrow status (P = 0.054). The median distant disease-free survival period was 78 months (95% confidence interval 73-82) in patients with negative bone marrow status and 72 months (95% CI 61-82) in patients with positive bone marrow status (P = 0.051). Multivariate analysis revealed the presence of ITC as a significant, independent risk factor for the subsequent development of distant metastases (relative risk 3.6, P = 0.046).
CONCLUSION: Despite the locoregional predominance of cervical carcinoma at the time of primary diagnosis, the presence of ITC in the bone marrow indicates an increased risk for the development of distant metastases. This information may prove useful to stratify patients for systemic treatment. Copyright 2003 American Cancer Society

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12518364     DOI: 10.1002/cncr.11066

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Interdisciplinary clinical evaluation of 58 patients with lumbar-vertebral metastases from cervico-uterine cancer.

Authors:  Víctor Valdespino Gómez; Juan M Salgado Cazares; Gaspar González Astudillo; Víctor E Valdespino Castillo
Journal:  Clin Transl Oncol       Date:  2005-11       Impact factor: 3.405

2.  Heterogeneity of ERα and ErbB2 Status in Cell Lines and Circulating Tumor Cells of Metastatic Breast Cancer Patients.

Authors:  Carolin Bock; Brigitte Rack; Christina Kuhn; Simone Hofmann; Charlotte Finkenzeller; Bernadette Jäger; Udo Jeschke; Sophie F Doisneau-Sixou
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

3.  Fatal invasive cervical cancer secondary to untreated cervical dysplasia: a case report.

Authors:  Stephan Braun; Daniel Reimer; Isolde Strobl; Ulrike Wieland; Petra Wiesbauer; Elisabeth Müller-Holzner; Siegfried Fessler; Arthur Scherer; Christian Marth; Alain G Zeimet
Journal:  J Med Case Rep       Date:  2011-07-18

4.  Fluorescence Analysis of Vitamin D Receptor Status of Circulating Tumor Cells (CTCS) in Breast Cancer: From Cell Models to Metastatic Patients.

Authors:  Xi Zhang; Simone Hofmann; Brigitte Rack; Nadia Harbeck; Udo Jeschke; Sophie Sixou
Journal:  Int J Mol Sci       Date:  2017-06-20       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.